A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms
- First Posted Date
- 2016-07-22
- Last Posted Date
- 2017-07-26
- Lead Sponsor
- Celgene
- Target Recruit Count
- 117
- Registration Number
- NCT02842229
- Locations
- 🇪🇸
Hospital La Fe, Valencia, Spain
🇪🇸Hospital de Segovia, Segovia, Spain
🇪🇸Hospital Txagorritxu, Vitoria, Álava, Spain
Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects
- First Posted Date
- 2016-07-01
- Last Posted Date
- 2016-10-18
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 36
- Registration Number
- NCT02820935
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Celgene
- Target Recruit Count
- 37
- Registration Number
- NCT02807454
- Locations
- 🇺🇸
UCLA Division of Hematology Oncology, Los Angeles, California, United States
🇨🇦Local Institution - 103, Saint John, New Brunswick, Canada
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS
- First Posted Date
- 2016-06-13
- Last Posted Date
- 2018-03-27
- Lead Sponsor
- Celgene
- Target Recruit Count
- 22
- Registration Number
- NCT02797015
- Locations
- 🇺🇸
Breastlink Medical Group, Inc., Long Beach, California, United States
🇺🇸Multiple Sclerosis Center at UCSF, San Francisco, California, United States
🇺🇸Raleigh Neurology Associates PA, Raleigh, North Carolina, United States
Longterm Follow-up of Subjects Treated With bb2121
- First Posted Date
- 2016-06-01
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- Celgene
- Target Recruit Count
- 50
- Registration Number
- NCT02786511
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸Stanford Cancer Center, Palo Alto, California, United States
An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2016-05-18
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Celgene
- Target Recruit Count
- 213
- Registration Number
- NCT02775903
- Locations
- 🇧🇪
Grand Hopital de Charleroi, Charleroi, Belgium
🇦🇹Salzburger Landkliniken St. Johanns-Spital, Salzburg, Austria
🇦🇹AKH Wien, Wein, Austria
A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-05-16
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 466
- Registration Number
- NCT02773030
- Locations
- 🇺🇸
Local Institution - 101, Atlanta, Georgia, United States
🇺🇸Local Institution - 108, Hackensack, New Jersey, United States
🇺🇸Local Institution - 115, Boston, Massachusetts, United States
Revlimid® Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM])
- Conditions
- First Posted Date
- 2016-04-18
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Celgene
- Target Recruit Count
- 578
- Registration Number
- NCT02741544
- Locations
- 🇯🇵
Shinko Hospital, Kobe, Hyogo, Japan
A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-04-11
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 106
- Registration Number
- NCT02733042
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸Jefferson Medical Oncology Associates, Philadelphia, Pennsylvania, United States
🇫🇷Centre Hospitalier Universitaire d'Avicennes, Bobigny Cedex, France
Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2016-02-26
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Celgene
- Target Recruit Count
- 22
- Registration Number
- NCT02692339
- Locations
- 🇵🇹
Hospital Professor Doutor Fernando Fonseca, E.P.E., Amadora, Portugal
🇵🇹Hospital Central de Faro, Faro, Portugal
🇵🇹Fundação Champalimaud, Lisboa, Portugal